Cannabidiol

Epidiolex, Epidyolex (cannabidiol) is a small molecule pharmaceutical. Cannabidiol was first approved as Epidiolex on 2018-09-28. It is used to treat anxiety, lennox gastaut syndrome, myoclonic epilepsies, and pain in the USA. It has been approved in Europe to treat lennox gastaut syndrome and myoclonic epilepsies. It is known to target N-arachidonyl glycine receptor, transient receptor potential cation channel subfamily V member 2, G-protein coupled receptor 55, transient receptor potential cation channel subfamily M member 8, transient receptor potential cation channel subfamily A member 1, transient receptor potential cation channel subfamily V member 3, and cannabinoid receptor 1. Epidiolex's patents are valid until 2035-10-14 (FDA).